FMP
VolitionRx Limited
VNRX
AMEX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
0.46 USD
-0.0399 (-8.67%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
470.7M
525.6M
746.2M
921.9M
807.2M
937.84M
1.09B
1.27B
1.47B
1.71B
-
11.66
41.97
23.55
-12.44
16.18
16.18
16.18
16.18
-73.6M
-173.9M
-131.2M
-71.6M
-145.2M
-172.67M
-200.62M
-233.09M
-270.82M
-314.65M
-15.64
-33.09
-17.58
-7.77
-17.99
-18.41
-18.41
-18.41
-18.41
-170.7M
-294.8M
-261M
-235.6M
-326.2M
-362.57M
-421.25M
-489.42M
-568.64M
-660.67M
-36.27
-56.09
-34.98
-25.56
-40.41
-38.66
-38.66
-38.66
-38.66
97.1M
120.9M
129.8M
164M
181M
189.89M
220.62M
256.33M
297.82M
346.02M
20.63
23
17.39
17.79
22.42
20.25
20.25
20.25
20.25
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)